XOMA Corporation (XOMAP)

XOMA Corporation (XOMAP) Healthcare & Pipeline Overview

XOMA Corporation is a biotechnology royalty aggregator specializing in early to mid-stage clinical assets, leveraging a portfolio of approximately 70 assets to enhance human health through strategic partnerships with pharmaceutical and biotechnology companies.

What Is the Investment Thesis for XOMAP?

XOMA Corporation's investment thesis is built on its unique position as a biotechnology royalty aggregator, which allows it to leverage a diversified portfolio of approximately 70 clinical assets. The company's focus on early to mid-stage clinical candidates, particularly those in Phase 1 and 2 trials, presents substantial growth opportunities as these assets progress toward commercialization. With a profit margin of 56.4% and a gross margin of 94.3%, XOMA demonstrates strong financial health and operational efficiency. The biotechnology sector is projected to grow significantly, driven by increasing demand for innovative therapies, which positions XOMA favorably to capitalize on this trend. Additionally, the company's low beta of 0.68 indicates lower volatility compared to the broader market, making it an appealing option for risk-averse investors. As XOMA continues to expand its portfolio and establish new partnerships, it is well-positioned to enhance shareholder value in the coming years.

Based on FMP financials and quantitative analysis

XOMAP Key Highlights

• Market capitalization of $301.22M reflects a robust position in the biotechnology sector.
• P/E ratio of 22.6 indicates a premium valuation relative to industry peers, suggesting strong growth expectations.
• Profit margin of 56.4% showcases XOMA's operational efficiency and ability to generate substantial profits.
• Gross margin of 94.3% highlights the company's strong pricing power and cost management.
• Beta of 0.68 indicates lower volatility compared to the market, appealing to risk-sensitive investors.

Who Are XOMAP's Competitors?

XOMAP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are XOMAP's Key Strengths?

• Strong profit margin of 56.4% indicates operational efficiency.
• Diverse portfolio of approximately 70 assets mitigates risk.
• Established presence in key markets enhances growth potential.
• Expertise in acquiring early to mid-stage clinical assets.

What Are XOMAP's Weaknesses?

• Limited scale with only 13 employees may restrict growth capacity.
• Dependence on partnerships for commercialization can pose risks.
• No dividend yield may deter income-focused investors.
• Focus on early-stage assets may result in longer timelines for revenue.

What Could Drive XOMAP Stock Higher?

• Expansion of partnerships with pharmaceutical companies to enhance asset commercialization.
• Development of clinical assets in the portfolio, progressing through Phase 1 and 2 trials.
• Potential acquisitions of new therapeutic candidates to diversify the portfolio.
• Engagement in strategic collaborations to enhance research and development efforts.

What Are the Key Risks for XOMAP?

• Financial-distress signal — its Altman Z-Score of -4.08 sits in the distress zone (elevated bankruptcy risk).
• Dependence on successful commercialization of licensed assets poses financial risks.
• Regulatory challenges in the biotechnology sector may impact operations.
• Market competition could affect the company's ability to secure new partnerships.
• Economic downturns may influence investor sentiment and funding availability.

What Are the Growth Opportunities for XOMAP?

• Expansion into new therapeutic areas: XOMA Corporation has opportunities to expand its portfolio by acquiring rights to promising therapeutic candidates in emerging areas such as gene therapy and immuno-oncology. The global gene therapy market is projected to reach $13.3 billion by 2026, growing at a CAGR of 26.5%. By strategically investing in these high-growth areas, XOMA can enhance its revenue streams and diversify its asset base.
• Geographic market expansion: With its established presence in Europe, the United States, and the Asia Pacific, XOMA has the potential to further penetrate these markets by forming new partnerships with local biotech firms. The Asia Pacific biotechnology market is expected to grow significantly, driven by increased investment in healthcare and research. This expansion could lead to increased royalty revenues as more assets progress through clinical trials.
• Acquisition of high-potential clinical assets: XOMA's strategy of acquiring early to mid-stage clinical assets allows it to tap into the growing demand for innovative therapies. As the biotechnology sector evolves, there will be an increasing number of promising candidates seeking partners for commercialization. By identifying and acquiring these assets, XOMA can enhance its portfolio and drive future revenue growth.
• Strategic partnerships with pharmaceutical companies: Collaborating with established pharmaceutical companies can provide XOMA with access to additional resources and expertise in bringing assets to market. These partnerships can accelerate the development of clinical candidates and increase the likelihood of successful commercialization, thereby enhancing XOMA's royalty income.
• Increased focus on rare diseases: The growing emphasis on developing treatments for rare diseases presents a significant opportunity for XOMA. The global market for rare disease therapies is projected to exceed $300 billion by 2025. By acquiring rights to innovative therapies targeting rare diseases, XOMA can position itself as a leader in this niche market and benefit from the associated royalty revenues.

What Opportunities Does XOMAP Have?

• Expansion into high-growth therapeutic areas like gene therapy.
• Potential for increased partnerships with pharmaceutical companies.
• Growing demand for rare disease therapies presents new avenues.
• Geographic expansion into emerging markets can enhance revenue.

What Threats Does XOMAP Face?

• Intense competition from established biotechnology firms.
• Regulatory challenges in the biotechnology sector.
• Market volatility affecting investor sentiment and funding.
• Potential for clinical trial failures impacting asset value.

What Are XOMAP's Competitive Advantages?

• Strong portfolio of approximately 70 clinical assets provides diversification.
• Focus on early to mid-stage candidates reduces competition and risk.
• Established relationships with pharmaceutical companies enhance partnership opportunities.
• Expertise in identifying high-potential therapeutic candidates strengthens market position.
• Operational efficiency demonstrated by high profit and gross margins.

What Does XOMAP Do?

Founded in 1981, XOMA Corporation has established itself as a prominent player in the biotechnology sector, specifically as a royalty aggregator. Headquartered in Emeryville, California, the company operates across Europe, the United States, and the Asia Pacific, focusing on acquiring potential future economic rights associated with pre-commercial therapeutic candidates. XOMA's business model revolves around identifying and securing early to mid-stage clinical assets, particularly those in Phase 1 and 2 clinical trials, which exhibit significant commercial sales potential. The company has successfully built a diverse portfolio consisting of approximately 70 assets, which it licenses to various pharmaceutical and biotechnology partners. This strategic approach not only enhances human health but also positions XOMA to capitalize on the growing demand for innovative therapeutic solutions. Over the years, XOMA has evolved from a traditional biotechnology firm into a specialized aggregator, allowing it to mitigate risks while maximizing returns from its investments in promising clinical candidates. The company’s commitment to advancing healthcare through strategic partnerships and its focus on high-potential therapeutic areas have solidified its reputation in the industry, making it a key player in the biotechnology landscape.

What Products and Services Does XOMAP Offer?

• Acquires future economic rights to pre-commercial therapeutic candidates.
• Focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 trials.
• Licenses assets to pharmaceutical and biotechnology companies for commercialization.
• Operates in multiple regions, including Europe, the United States, and the Asia Pacific.
• Maintains a diversified portfolio of approximately 70 assets.
• Engages in partnerships to enhance human health through innovative therapies.

How Does XOMAP Make Money?

• Generates revenue through royalties from licensed therapeutic candidates.
• Acquires potential future economic rights to promising clinical assets.
• Focuses on early to mid-stage assets to maximize growth potential.
• Licenses assets to established pharmaceutical companies for commercialization.
• Mitigates risks by diversifying its portfolio across various therapeutic areas.

What Industry Does XOMAP Operate In?

The biotechnology industry is experiencing rapid growth, driven by advancements in technology and an increasing focus on personalized medicine. The global biotechnology market is expected to reach approximately $2.4 trillion by 2028, growing at a CAGR of around 7.4%. XOMA Corporation's unique business model as a royalty aggregator positions it strategically within this expanding market, enabling it to capitalize on the rising demand for innovative therapeutic solutions. The competitive landscape includes various biotech firms, but XOMA's focus on early to mid-stage assets differentiates it from traditional biotechnology companies, allowing it to mitigate risks while maximizing potential returns.

Who Are XOMAP's Key Customers?

• Pharmaceutical companies seeking to license innovative therapeutic candidates.
• Biotechnology firms looking for partners to commercialize their assets.
• Investors interested in biotechnology royalty aggregation opportunities.
• Healthcare providers benefiting from advanced therapeutic solutions.
• Research institutions collaborating on clinical asset development.

FY2026 estForward Outlook

Wall Street analysts project XOMA Corporation revenue of about $60.7M for fiscal 2026, with EPS near $0.79. The estimate reflects 3 contributing analysts.

XOMAP Valuation & Market Position

With a $301.22M market cap, XOMA Corporation sits in the small-cap segment of the market. Relative to its peer group, XOMAP's quantitative score of 30/100 is below the peer average of 85/100.

ROE 30%Key Financial Metrics

Return on equity for XOMA Corporation stands at 30.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 11.6%, showing how much profit it generates from its asset base. XOMAP trades at a trailing price-to-earnings ratio of 22.60, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 1.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.59 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.2%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 6/9Financial Health

XOMA Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -4.08 places it in the distress zone, a signal of elevated financial risk.

Company Profile

XOMA Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in EmeryVille, US. The company is led by CEO Owen Hughes Jr.. XOMAP has traded publicly since 2020.

XOMAP Financials

XOMAP Latest News

No recent news available for XOMAP.

XOMAP Analyst Consensus

XOMAP MoonshotScore

XOMA Corporation Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources